カテゴリ： GlobalData, アメリカ, 企業調査

Regen BioPharma Inc (RGBP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Regen BioPharma Inc (RGBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8245
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Regen BioPharma Inc (Regen BioPharma), a subsidiary of Bio-Matrix Scientific Group Inc, is an immunology and immunotherapy space provider. The company concentrates on the development of immunotherapies and cancer stem cell therapies. Its product pipeline includes HemaXellerate, dCellVax, DiffronC, small molecule targeting cancer stem cell genes, telomeres and genomic integrity. Regen BioPharma provides products for aplastic anemia, myelodysplastic syndrome, solid tumors and acute leukemia, breast cancer, hematopoiesis and liver cancer, among others. The company spans its expertise in the development of therapies including small molecules, stem cell treatments and the body’s own immune system. Regen BioPharma is headquartered in La Mesa, California, the US.

Regen BioPharma Inc (RGBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Regen BioPharma Acquires Labs Facilities in US 13
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14
Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15
Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16
Venture Financing 17
Regen BioPharma Raises US$20 Million In Venture Financing 17
Partnerships 18
Regen BioPharma Enters into Agreement with ChemDiv 18
Regen BioPharma to Enter into Agreement with Eli Lilly 19
Regen BioPharma Enters into Research Agreement with National Institutes of Health 20
Licensing Agreements 21
CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 22
Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 24
Equity Offering 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 26
Regen BioPharma Raises Funding in Private Placement of Common Stock 27
Regen BioPharma Raises Funds in Private Placement of Shares 28
Regen BioPharma Raises Funds in Private Placement of Units 29
Regen BioPharma Raises Funding in Private Placement of Series A Preferred Stock 30
Regen BioPharma Raises USD0.15 Million in Private Placement of Units 31
Regen BioPharma Raises USD0.1 Million in Private Placement of Series A Preferred Stock 32
Regen BioPharma Raises funds in Private Placement 33
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 34
Regen BioPharma Raises Funds in Private Placement of Series A Preferred Stock 35
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 36
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 37
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 38
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 39
Debt Offering 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 41
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 42
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 43
Regen BioPharma Inc – Key Competitors 44
Regen BioPharma Inc – Key Employees 45
Regen BioPharma Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Corporate Communications 47
Oct 30, 2017: Regen BioPharma Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB) 47
Product News 48
11/08/2017: Regen BioPharma’s Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs 48
Oct 23, 2017: Regen BioPharma Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6 49
10/16/2017: Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases 50
10/03/2017: Regen BioPharma Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6 51
09/06/2017: Regen BioPharma Researchers Identify Key Structure in Compounds that Activate NR2F6 52
07/25/2017: Regen BioPharma Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators 53
Jul 12, 2017: Regen BioPharma Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint 54
May 16, 2017: Regen BioPharma Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases 55
Apr 18, 2017: Regen BioPharma Identifies Three New Series of Compounds That Activate NR2F6 56
Apr 12, 2017: Regen BioPharma Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6 57
Mar 23, 2017: Regen BioPharma Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Regen BioPharma Acquires Labs Facilities in US 13
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14
Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15
Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16
Regen BioPharma Raises US$20 Million In Venture Financing 17
Regen BioPharma Enters into Agreement with ChemDiv 18
Regen BioPharma to Enter into Agreement with Eli Lilly 19
Regen BioPharma Enters into Research Agreement with National Institutes of Health 20
CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 22
Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 24
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 26
Regen BioPharma Raises Funding in Private Placement of Common Stock 27
Regen BioPharma Raises Funds in Private Placement of Shares 28
Regen BioPharma Raises Funds in Private Placement of Units 29
Regen BioPharma Raises Funding in Private Placement of Series A Preferred Stock 30
Regen BioPharma Raises USD0.15 Million in Private Placement of Units 31
Regen BioPharma Raises USD0.1 Million in Private Placement of Series A Preferred Stock 32
Regen BioPharma Raises funds in Private Placement 33
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 34
Regen BioPharma Raises Funds in Private Placement of Series A Preferred Stock 35
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 36
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 37
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 38
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 39
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 41
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 42
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 43
Regen BioPharma Inc, Key Competitors 44
Regen BioPharma Inc, Key Employees 45
Regen BioPharma Inc, Subsidiaries 46

List of Figures
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Regen BioPharma Inc (RGBP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Axela Inc：医療機器：M&Aディール及び事業提携情報
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • GC Pharma (006280)：企業の財務・戦略的SWOT分析
    GC Pharma (006280) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Regal Petroleum Plc (RPT)：石油・ガス：M&Aディール及び事業提携情報
    Summary Regal Petroleum Plc (Regal), a subsidiary of Energees Investments Ltd, is an oil and gas company that conducts reviews on oil and gas projects. The company operates two gas and condensate fields such as Mekhediviska - Golotovschinska and Svyrydivske located in Dneipner-Donets basin in the no …
  • Chevron Corporation (CVX)-石油・ガス分野：企業M&A・提携分析
    Summary Chevron Corporation (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for produces and transports cr …
  • Buy It Direct Ltd：企業の戦略的SWOT分析
    Buy It Direct Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Discover Financial Services：戦略・SWOT・企業財務分析
    Discover Financial Services - Strategy, SWOT and Corporate Finance Report Summary Discover Financial Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Medpace Inc (MEDP)：企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • Aon Plc：企業の戦略・SWOT・財務分析
    Aon Plc - Strategy, SWOT and Corporate Finance Report Summary Aon Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Abengoa, S.A.：企業の戦略・SWOT・財務情報
    Abengoa, S.A. - Strategy, SWOT and Corporate Finance Report Summary Abengoa, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • PsiOxus Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary PsiOxus Therapeutics Ltd (PsiOxus), formerly known as Myotec Therapeutics Ltd is a drug company that develops novel therapeutics for cancer and other clinically unmet diseases. The company provides pipeline product portfolio such as an oncolytic vaccine and a dual action anabolic catabolic t …
  • Chembond Chemicals Ltd (530871)：企業の財務・戦略的SWOT分析
    Chembond Chemicals Ltd (530871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • BBVA Banco Frances S.A.：企業の戦略・SWOT・財務分析
    BBVA Banco Frances S.A. - Strategy, SWOT and Corporate Finance Report Summary BBVA Banco Frances S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Active Motif Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Active Motif Inc (Active Motif) is a healthcare company that develops and delivers biological research tools. The company’s products include extracts, antibodies, reporter assays, fluorescent dyes, kits, cell, acid, and tissue extracts, molecules and recombinant proteins, among others. It of …
  • Callaway Golf Co (ELY)：企業の財務・戦略的SWOT分析
    Callaway Golf Co (ELY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Wells Fargo Private Bank：企業の戦略・SWOT・財務分析
    Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report Summary Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Flex Ltd (FLEX)：電力：M&Aディール及び事業提携情報
    Summary Flex Ltd (Flex) provides design, engineering, manufacturing, and supply chain services to electronics original equipment manufacturers. The company, through its Sketch-to-Scale concept, provides concept design, prototype creation, intellectual property protection, new product introduction, a …
  • Ignyta Inc (RXDX)-医療機器分野：企業M&A・提携分析
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnost …
  • Grupo Nutresa SA (NUTRESA)：企業の財務・戦略的SWOT分析
    Grupo Nutresa SA (NUTRESA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Biosilu Healthcare AG (1YA)-製薬・医療分野：企業M&A・提携分析
    Summary Biosilu Healthcare AG (Biosilu Healthcare), formerly Amp Biosimilars AG is a life science company that develops and commercializes biopharmaceuticals. The company's product pipeline comprises biosimilar development projects on immune disorders and cancer. It offers products in therapeutic ar …
  • Covance Inc：企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆